Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat dose-titration study in children and adolescents with pulmonary arterial hypertension
2023-503536-40-00Phase 3Authorised
- Sponsor
- Bayer
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of riociguat in pulmonary arterial hypertension (PAH), sponsored by Bayer. Primary endpoints: Incidence of adverse events and serious adverse events, Vital signs and 2 more. Planned start Feb 2016; status: authorised.
02
Drugs
riociguat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2023-503536-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503536-40-00.